Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Hydrogen Sulfide as a Blood Biomarker for Cognitive Impairment

Start: April 1, 2021
End: May 2027
Enrollment: 100

What Is This Study About?

Diseases that impact blood vessels, such as high blood pressure and type 2 diabetes, are associated with the risk of dementia. This study will evaluate whether measuring hydrogen sulfide, a biomarker of blood vessel damage, can be used to detect blood vessel changes in the brain associated with dementia. Participants with cognitive impairment due to Alzheimer's disease or related dementia, and participants with no cognitive impairment will provide blood samples and undergo MRI brain scans. Researchers will measure hydrogen sulfide levels and changes in brain volume. In addition, because previous studies suggest that dementia risk varies by race and gender, study outcomes will be compared across these groups as well. 

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 100 Years

Must have:

  • Participants with either:
    • No cognitive impairment
    • Cognitive problems due to Alzheimer's or related dementia
  • English as a primary language
  • Dosage for any current medications must be stable for more than four weeks
  • Adequate vision and hearing to perform study tests
  • Able to provide a history of education to exclude any developmental cognitive abnormalities

Must NOT have:

  • History of significant neurological disease or mental illness, or chronic kidney disease
  • Current moderate to severe depression (Geriatric Depression Scale score > 6)
  • Substance abuse within the past two years
  • Any condition that could make having an MRI brain scan unsafe (e.g., metal shrapnel, pacemaker, severe claustrophobia)  
  • Abnormal findings on MRI brain scan that could interfere with study
  • Use of research drug within one month prior to participation in this study
  • Any unstable medical condition that could interfere with the completion of the study

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Louisiana State University Health Sciences Center Shreveport

Source: ClinicalTrials.gov ID: NCT05060848

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health